ATE342892T1 - Pyrimidine verbindungen - Google Patents

Pyrimidine verbindungen

Info

Publication number: ATE342892T1
Authority: AT; Austria
Prior art keywords: sub; alkyl; formula; sup; substituent
Prior art date: 1998-08-29

Application number

AT99940401T

Other languages

English (en)

Inventor

Gloria Anne Breault

Janet Elizabeth Pease

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-29

Filing date

1999-08-24

Publication date

2006-11-15

1998-08-29 Priority claimed from GBGB9818989.7A external-priority patent/GB9818989D0/en

1998-12-24 Priority claimed from GBGB9828433.4A external-priority patent/GB9828433D0/en

1999-08-24 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2006-11-15 Application granted granted Critical

2006-11-15 Publication of ATE342892T1 publication Critical patent/ATE342892T1/de

Links

CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 4
125000001424 substituent group Chemical group 0.000 abstract 3
125000003342 alkenyl group Chemical group 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
-1 1,2,3,4-tetrahydronaphthyl Chemical group 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000004414 alkyl thio group Chemical group 0.000 abstract 1
125000000304 alkynyl group Chemical group 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
229910052799 carbon Inorganic materials 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
125000001624 naphthyl group Chemical group 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
150000003230 pyrimidines Chemical class 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AT99940401T 1998-08-29 1999-08-24 Pyrimidine verbindungen ATE342892T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9818989.7A GB9818989D0 (en)	1998-08-29	1998-08-29	Chemical compounds
GBGB9828433.4A GB9828433D0 (en)	1998-12-24	1998-12-24	Chemical compounds

Publications (1)

Publication Number	Publication Date
ATE342892T1 true ATE342892T1 (de)	2006-11-15

Family

ID=26314296

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99940401T ATE342892T1 (de)	1998-08-29	1999-08-24	Pyrimidine verbindungen

Country Status (8)

Country	Link
US (1)	US7176212B2 (de)
EP (1)	EP1107957B1 (de)
JP (1)	JP2002523497A (de)
AT (1)	ATE342892T1 (de)
AU (1)	AU5438299A (de)
DE (1)	DE69933680T2 (de)
ES (1)	ES2274634T3 (de)
WO (1)	WO2000012485A1 (de)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7772432B2 (en)	1991-09-19	2010-08-10	Astrazeneca Ab	Amidobenzamide derivatives which are useful as cytokine inhibitors
AU5438299A (en)	1998-08-29	2000-03-21	Astrazeneca Ab	Pyrimidine compounds
ATE336484T1 (de)	1998-08-29	2006-09-15	Astrazeneca Ab	Pyrimidine verbindungen
CN1158266C (zh)	1998-10-01	2004-07-21	阿斯特拉曾尼卡有限公司	化合物
GB9828511D0 (en)	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
GB9905075D0 (en)	1999-03-06	1999-04-28	Zeneca Ltd	Chemical compounds
DE60010448T2 (de)	1999-03-17	2005-04-07	Astrazeneca Ab	Amid-derivate
GB9907658D0 (en)	1999-04-06	1999-05-26	Zeneca Ltd	Chemical compounds
GB9919778D0 (en)	1999-08-21	1999-10-27	Zeneca Ltd	Chemical compounds
MXPA02003436A (es)	1999-10-07	2002-08-20	Amgen Inc	Inhibidores de triazina cinasa.
GB9924092D0 (en)	1999-10-13	1999-12-15	Zeneca Ltd	Pyrimidine derivatives
KR20030024659A (ko)	2000-02-17	2003-03-26	암겐 인코포레이티드	키나제 억제제
GB0004890D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004887D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004888D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004886D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0007371D0 (en)	2000-03-28	2000-05-17	Astrazeneca Uk Ltd	Chemical compounds
GB2361236B (en)	2000-03-29	2002-04-24	Cyclacel Ltd	Pyrimidines useful against proliferative disorders
GB0016877D0 (en)	2000-07-11	2000-08-30	Astrazeneca Ab	Chemical compounds
MXPA03001452A (es)	2000-08-18	2004-05-04	Agouron Pharma	Hidroximino-fluorenos heterociclicos y su uso para la inhibicion de las proteinas cinasas.
GB0021726D0 (en)	2000-09-05	2000-10-18	Astrazeneca Ab	Chemical compounds
MXPA03005696A (es)	2000-12-21	2003-10-06	Glaxo Group Ltd	Pirimidinaminas como moduladores de angiogenesis.
US6756374B2 (en)	2001-01-22	2004-06-29	Hoffmann-La Roche Inc.	Diaminothiazoles having antiproliferative activity
GB0103926D0 (en)	2001-02-17	2001-04-04	Astrazeneca Ab	Chemical compounds
GB0113041D0 (en)	2001-05-30	2001-07-18	Astrazeneca Ab	Chemical compounds
US7638522B2 (en)	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en)	2001-08-13	2012-01-24	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
JP4460292B2 (ja)	2001-10-17	2010-05-12	ベーリンガーインゲルハイムファルマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト	ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法
EP1453516A2 (de)	2001-10-17	2004-09-08	Boehringer Ingelheim Pharma GmbH & Co.KG	5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
IL162210A0 (en) *	2001-11-28	2005-11-20	Btg Int Ltd	Preventives or remedies for alzheimer's disease oramyloid protein fibrosis inhibitors containing ni trogen-containing heteroaryl
SE0104140D0 (sv)	2001-12-07	2001-12-07	Astrazeneca Ab	Novel Compounds
NZ534069A (en)	2002-01-22	2007-03-30	Warner Lambert Co	2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
US7459455B2 (en)	2002-02-08	2008-12-02	Smithkline Beecham Corporation	Pyrimidine compounds
GB0205690D0 (en)	2002-03-09	2002-04-24	Astrazeneca Ab	Chemical compounds
GB0205693D0 (en)	2002-03-09	2002-04-24	Astrazeneca Ab	Chemical compounds
WO2003076434A1 (en)	2002-03-09	2003-09-18	Astrazeneca Ab	4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0205688D0 (en)	2002-03-09	2002-04-24	Astrazeneca Ab	Chemical compounds
GB0206215D0 (en) *	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
IL166241A0 (en)	2002-07-29	2006-01-15	Rigel Pharmaceuticals Inc	Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
US7399856B2 (en)	2002-08-09	2008-07-15	Janssen Pharmaceutica N.V.	Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile
UA80767C2 (en) *	2002-12-20	2007-10-25	Pfizer Prod Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
SI1625121T1 (sl)	2002-12-20	2010-04-30	Pfizer Prod Inc	Derivati pirimidina za zdravljenje abnormalne rasti celic
US7109337B2 (en)	2002-12-20	2006-09-19	Pfizer Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
US7157455B2 (en)	2003-02-10	2007-01-02	Hoffmann-La Roche Inc.	4-Aminopyrimidine-5-one derivatives
ES2325440T3 (es)	2003-02-20	2009-09-04	Smithkline Beecham Corporation	Compuestos de pirimidina.
GB0305929D0 (en)	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
GB0311274D0 (en)	2003-05-16	2003-06-18	Astrazeneca Ab	Chemical compounds
GB0311276D0 (en)	2003-05-16	2003-06-18	Astrazeneca Ab	Chemical compounds
ES2421139T3 (es)	2003-07-30	2013-08-29	Rigel Pharmaceuticals, Inc.	Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
ATE542801T1 (de)	2003-08-15	2012-02-15	Novartis Ag	Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
GB0321710D0 (en) *	2003-09-16	2003-10-15	Novartis Ag	Organic compounds
ES2328820T3 (es)	2003-10-17	2009-11-18	Astrazeneca Ab	Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer.
GB0324790D0 (en)	2003-10-24	2003-11-26	Astrazeneca Ab	Amide derivatives
TW200528101A (en)	2004-02-03	2005-09-01	Astrazeneca Ab	Chemical compounds
US7211576B2 (en)	2004-04-20	2007-05-01	Hoffmann-La Roche Inc.	Diaminothiazoles
EP1758887A1 (de)	2004-05-14	2007-03-07	Pfizer Products Incorporated	Pyrimidinderivate zur behandlung von anormalem zellwachstum
MXPA06013164A (es)	2004-05-14	2007-02-13	Pfizer Prod Inc	Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
MXPA06011658A (es)	2004-05-14	2006-12-14	Pfizer Prod Inc	Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
EP1598343A1 (de) *	2004-05-19	2005-11-23	Boehringer Ingelheim International GmbH	2-Arylaminopyrimidine als PLK Inhibitoren
US7405220B2 (en)	2004-06-09	2008-07-29	Hoffmann-La Roche Inc.	Pyrazolopyrimidines
US7521457B2 (en) *	2004-08-20	2009-04-21	Boehringer Ingelheim International Gmbh	Pyrimidines as PLK inhibitors
CA2576159A1 (en)	2004-08-27	2006-03-02	Cyclacel Limited	Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
ATE540035T1 (de)	2004-11-24	2012-01-15	Rigel Pharmaceuticals Inc	Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
MY169441A (en) *	2004-12-08	2019-04-11	Janssen Pharmaceutica Nv	2,4, (4,6) pyrimidine derivatives
US20090099160A1 (en) *	2004-12-17	2009-04-16	David Andrews	4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors
US7449458B2 (en)	2005-01-19	2008-11-11	Rigel Pharmaceuticals, Inc.	Prodrugs of 2,4-pyrimidinediamine compounds and their uses
KR101362621B1 (ko)	2005-02-16	2014-02-13	아스트라제네카 아베	화합물
CA2608009A1 (en)	2005-05-16	2006-11-23	Astrazeneca Ab	Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
WO2006133426A2 (en)	2005-06-08	2006-12-14	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
FR2893941B1 (fr) *	2005-11-25	2009-06-05	Sanofi Aventis Sa	Nouveaux derives de 2,4-dianilinopyridines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
BRPI0614502A2 (pt) *	2005-07-30	2011-03-29	Astrazeneca Ab	Composto, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto
AU2006296386A1 (en)	2005-09-30	2007-04-05	Astrazeneca Ab	Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
BRPI0618011A2 (pt)	2005-10-28	2011-08-16	Astrazeneca Ab	composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
WO2007053452A1 (en) *	2005-11-01	2007-05-10	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
US7705009B2 (en)	2005-11-22	2010-04-27	Hoffman-La Roche Inc.	4-aminopyrimidine-5-thione derivatives
TW200736232A (en) *	2006-01-26	2007-10-01	Astrazeneca Ab	Pyrimidine derivatives
PE20080068A1 (es)	2006-05-15	2008-03-17	Boehringer Ingelheim Int	Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
TW200811169A (en) *	2006-05-26	2008-03-01	Astrazeneca Ab	Chemical compounds
AU2007257650A1 (en) *	2006-06-15	2007-12-21	Boehringer Ingelheim International Gmbh	2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase C-alpha
AU2007257701A1 (en) *	2006-06-15	2007-12-21	Boehringer Ingelheim International Gmbh	2-anilino-4-aminoalkyleneaminopyrimidines
JP5208123B2 (ja) *	2006-12-08	2013-06-12	アイアールエム・リミテッド・ライアビリティ・カンパニー	タンパク質キナーゼ阻害剤としての化合物および組成物
EA019941B1 (ru)	2006-12-08	2014-07-30	АйАрЭм ЭлЭлСи	Соединения и композиции в качестве ингибиторов протеинкиназы
UA99459C2 (en)	2007-05-04	2012-08-27	Астразенека Аб	9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
BRPI0815979A2 (pt)	2007-08-28	2017-06-13	Irm Llc	compostos e composições com inibidores de quinase, bem como uso dos mesmos
RU2490015C2 (ru)	2008-02-22	2013-08-20	Райджел Фармасьютикалз, Инк.	Применение 2,4-пиримидиндиаминов для лечения атеросклероза
US8445505B2 (en)	2008-06-25	2013-05-21	Irm Llc	Pyrimidine derivatives as kinase inhibitors
PE20100087A1 (es)	2008-06-25	2010-02-08	Irm Llc	Compuestos y composiciones como inhibidores de cinasa
AU2009262068C1 (en) *	2008-06-27	2015-07-02	Celgene Car Llc	Heteroaryl compounds and uses thereof
US11351168B1 (en)	2008-06-27	2022-06-07	Celgene Car Llc	2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
TW201024281A (en)	2008-11-24	2010-07-01	Boehringer Ingelheim Int	New compounds
AR074210A1 (es)	2008-11-24	2010-12-29	Boehringer Ingelheim Int	Derivados de pirimidina como inhibidores de ptk2-quinasa
US20110071158A1 (en) *	2009-03-18	2011-03-24	Boehringer Ingelheim International Gmbh	New compounds
KR101705158B1 (ko)	2009-05-05	2017-02-09	다나-파버 캔서 인스티튜트 인크.	Ｅｇｆｒ 억제제 및 질환 치료방법
TW201100441A (en) *	2009-06-01	2011-01-01	Osi Pharm Inc	Amino pyrimidine anticancer compounds
BR112012029647A2 (pt)	2010-05-21	2016-08-02	Chemilia Ab	novos derivados de pirimidinas
WO2011159726A2 (en)	2010-06-14	2011-12-22	The Scripps Research Institute	Reprogramming of cells to a new fate
PH12013500246A1 (en)	2010-08-10	2019-10-11	Celgene Avilomics Res Inc	Besylate salt of a btk inhibitor
BR112013010564B1 (pt)	2010-11-01	2021-09-21	Celgene Car Llc	Compostos heterocíclicos e composições compreendendo os mesmos
JP5956999B2 (ja)	2010-11-01	2016-07-27	セルジーンアヴィロミクスリサーチ，インコーポレイテッド	ヘテロアリール化合物およびその使用
EP2637502B1 (de)	2010-11-10	2018-01-10	Celgene CAR LLC	Mutanten-selektive egfr-hemmer und verwendungen davon
WO2012074951A1 (en)	2010-11-29	2012-06-07	OSI Pharmaceuticals, LLC	Macrocyclic kinase inhibitors
DK2675794T3 (da)	2011-02-17	2019-05-06	Cancer Therapeutics Crc Pty Ltd	Selektive fak-inhibitorer
WO2012110773A1 (en)	2011-02-17	2012-08-23	Cancer Therapeutics Crc Pty Limited	Fak inhibitors
MX2013010898A (es)	2011-03-24	2013-12-06	Chemilia Ab	Novedoso derivados de la pirimidina.
TWI548621B (zh)	2011-04-22	2016-09-11	標誌製藥公司	經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法
US8884006B2 (en) *	2011-09-19	2014-11-11	University Of Puerto Rico	Small-molecule inhibitors of Rac1 in metastatic breast cancer
JP2014532658A (ja)	2011-10-28	2014-12-08	セルジーンアヴィロミクスリサーチ，インコーポレイテッド	ブルトン型チロシンキナーゼ疾患または障害を治療する方法
ES2880109T3 (es)	2012-03-15	2021-11-23	Celgene Car Llc	Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
JP6317320B2 (ja)	2012-03-15	2018-04-25	セルジーンシーエーアールエルエルシー	上皮成長因子受容体キナーゼ阻害剤の塩
US9126950B2 (en)	2012-12-21	2015-09-08	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
CN105188371A (zh)	2013-02-08	2015-12-23	西建阿维拉米斯研究公司	Erk抑制剂及其用途
US9492471B2 (en)	2013-08-27	2016-11-15	Celgene Avilomics Research, Inc.	Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en)	2013-12-20	2016-08-16	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
NZ715903A (en)	2014-01-30	2017-06-30	Signal Pharm Llc	Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
WO2016025561A1 (en)	2014-08-13	2016-02-18	Celgene Avilomics Research, Inc.	Forms and compositions of an erk inhibitor
US10059689B2 (en) *	2014-10-14	2018-08-28	Calitor Sciences, Llc	Substituted heteroaryl compounds and methods of use
EP3712134B1 (de)	2014-12-16	2023-11-29	Signal Pharmaceuticals, LLC	Salze von 2-(tert-butylamino)-4-((1r, 3r, 4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidin-5-carboxamid
US9513297B2 (en)	2014-12-16	2016-12-06	Signal Pharmaceuticals, Llc	Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
EP3250557B1 (de)	2015-01-29	2024-11-20	Signal Pharmaceuticals, LLC	Isotopologe von 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidin-5-carboxamid
EP3325432B1 (de)	2015-07-24	2020-09-02	Celgene Corporation	Verfahren zur synthese von (1r, 2r, 5r)-5-amino-2-methylcyclohexanolhydrochlorid und nützliche zwischenprodukte darin
CN112390760B (zh) *	2020-10-15	2022-07-29	北京师范大学	靶向fak的化合物及其制备方法和应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4946956A (en)	1988-09-21	1990-08-07	Uniroyal Chemical Company, Inc.	Arylenediamine substituted pyrimidines
HU206337B (en)	1988-12-29	1992-10-28	Mitsui Petrochemical Ind	Process for producing pyrimidine derivatives and pharmaceutical compositions
US4983608A (en) *	1989-09-05	1991-01-08	Hoechst-Roussell Pharmaceuticals, Inc.	N-substituted-4-pyrimidinamines and pyrimidinediamines
GB9012592D0 (en)	1990-06-06	1990-07-25	Smithkline Beecham Intercredit	Compounds
DE69222637T2 (de)	1991-05-10	1998-02-26	Rhone Poulenc Rorer Int	Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US5516775A (en) *	1992-08-31	1996-05-14	Ciba-Geigy Corporation	Further use of pyrimidine derivatives
ES2149213T3 (es) *	1992-10-05	2000-11-01	Ube Industries	Compuesto de pirimidina.
AU693475B2 (en)	1993-10-01	1998-07-02	Novartis Ag	Pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en)	1993-10-01	1996-08-06	Ciba-Geigy Corporation	Pyrimidine derivatives
DE69429078T2 (de)	1993-10-01	2002-07-11	Novartis Ag, Basel	Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung
PT672042E (pt)	1993-10-01	2006-08-31	Novartis Ag	Derivados de pirimidinoamina farmacologicamente activos e processos para a sua preparacao
GB9325217D0 (en)	1993-12-09	1994-02-09	Zeneca Ltd	Pyrimidine derivatives
EP0775120B1 (de)	1994-08-13	2003-06-04	Yuhan Corporation	Neue pyrimidinderivate und verfahren zu ihrer herstellung
EP0813525B9 (de)	1995-03-10	2004-02-04	Berlex Laboratories, Inc.	Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
IL118544A (en)	1995-06-07	2001-08-08	Smithkline Beecham Corp	History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US5739143A (en) *	1995-06-07	1998-04-14	Smithkline Beecham Corporation	Imidazole compounds and compositions
GB9523675D0 (en) *	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
WO1997035856A1 (en)	1996-03-25	1997-10-02	Smithkline Beecham Corporation	Novel treatment for cns injuries
AU708883B2 (en) *	1996-06-10	1999-08-12	Merck & Co., Inc.	Substituted imidazoles having cytokine inhibitory activity
GB9619284D0 (en)	1996-09-16	1996-10-30	Celltech Therapeutics Ltd	Chemical compounds
AU5147598A (en)	1996-10-17	1998-05-11	Smithkline Beecham Corporation	Methods for reversibly inhibiting myelopoiesis in mammalian tissue
GB9622363D0 (en)	1996-10-28	1997-01-08	Celltech Therapeutics Ltd	Chemical compounds
ZA9711092B (en)	1996-12-11	1999-07-22	Smithkline Beecham Corp	Novel compounds.
ES2301194T3 (es)	1997-02-05	2008-06-16	Warner-Lambert Company Llc	Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
DE19710435A1 (de)	1997-03-13	1998-09-17	Hoechst Ag	Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
GB9705361D0 (en)	1997-03-14	1997-04-30	Celltech Therapeutics Ltd	Chemical compounds
CA2291709A1 (en)	1997-05-30	1998-12-03	Merck & Co., Inc.	Novel angiogenesis inhibitors
AU742293B2 (en)	1997-06-12	2001-12-20	Aventis Pharma Limited	Imidazolyl-cyclic acetals
TW517055B (en)	1997-07-02	2003-01-11	Smithkline Beecham Corp	Novel substituted imidazole compounds
EP1021173A1 (de)	1997-10-10	2000-07-26	Imperial College Innovations Limited	Verwendung von cytokin-unterdrückenden verbindungen (csaid) zur behandlung von gebärmutterkontraktionen
ATE401312T1 (de)	1997-12-15	2008-08-15	Astellas Pharma Inc	Pyrimidin-5-carboxamid-derivate
JP2001526230A (ja)	1997-12-19	2001-12-18	スミスクライン・ビーチャム・コーポレイション	ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用
NZ506679A (en)	1998-03-27	2002-11-26	Janssen Pharmaceutica Nv	HIV inhibiting pyrimidine derivatives
AU5438299A (en)	1998-08-29	2000-03-21	Astrazeneca Ab	Pyrimidine compounds
ATE336484T1 (de)	1998-08-29	2006-09-15	Astrazeneca Ab	Pyrimidine verbindungen
CZ2001959A3 (cs)	1998-09-18	2001-12-12	Basf Aktiengesellschaft	4-Aminopyrrolopyrimidiny jako inhibitory kinasy
NZ510588A (en)	1998-09-18	2003-08-29	Abbott Gmbh & Co	Pyrrolopyrimidines as protein kinase inhibitors
AU764479B2 (en)	1998-10-29	2003-08-21	Bristol-Myers Squibb Company	Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme
WO2000026209A1 (en)	1998-11-03	2000-05-11	Novartis Ag	Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
GB9828511D0 (en) *	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
IL144675A0 (en)	1999-02-01	2002-05-23	Cv Therapeutics Inc	PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-α
GB9903762D0 (en)	1999-02-18	1999-04-14	Novartis Ag	Organic compounds
GB9905075D0 (en)	1999-03-06	1999-04-28	Zeneca Ltd	Chemical compounds
US6627633B2 (en)	1999-03-17	2003-09-30	Albany Molecular Research, Inc.	6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
GB9907658D0 (en) *	1999-04-06	1999-05-26	Zeneca Ltd	Chemical compounds
GB9914258D0 (en)	1999-06-18	1999-08-18	Celltech Therapeutics Ltd	Chemical compounds
GB9919778D0 (en)	1999-08-21	1999-10-27	Zeneca Ltd	Chemical compounds
GB9924862D0 (en)	1999-10-20	1999-12-22	Celltech Therapeutics Ltd	Chemical compounds
ATE311385T1 (de)	1999-10-27	2005-12-15	Novartis Pharma Gmbh	Thiazol und imidazo(4,5-b)pyridin verbindungen und ihre verwendung als pharmazeutika
GB0004887D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004890D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004886D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004888D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds

1999
- 1999-08-24 AU AU54382/99A patent/AU5438299A/en not_active Abandoned
- 1999-08-24 EP EP99940401A patent/EP1107957B1/de not_active Expired - Lifetime
- 1999-08-24 JP JP2000567515A patent/JP2002523497A/ja active Pending
- 1999-08-24 AT AT99940401T patent/ATE342892T1/de not_active IP Right Cessation
- 1999-08-24 WO PCT/GB1999/002790 patent/WO2000012485A1/en not_active Ceased
- 1999-08-24 ES ES99940401T patent/ES2274634T3/es not_active Expired - Lifetime
- 1999-08-24 DE DE69933680T patent/DE69933680T2/de not_active Expired - Fee Related
2004
- 2004-02-04 US US10/771,118 patent/US7176212B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2000012485A1 (en)	2000-03-09
US20050090493A1 (en)	2005-04-28
DE69933680D1 (de)	2006-11-30
ES2274634T3 (es)	2007-05-16
HK1035531A1 (en)	2001-11-30
EP1107957A1 (de)	2001-06-20
US7176212B2 (en)	2007-02-13
DE69933680T2 (de)	2007-08-23
EP1107957B1 (de)	2006-10-18
AU5438299A (en)	2000-03-21
JP2002523497A (ja)	2002-07-30

Legal Events

Date	Code	Title	Description
2007-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69933680D1 (de)	2006-11-30	Pyrimidine verbindungen
DE69932828D1 (de)	2006-09-28	Pyrimidine verbindungen
JO2035B1 (en)	1999-05-15	Pyrazine compounds
MY118904A (en)	2005-02-28	4-oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents
TW343971B (en)	1998-11-01	2,4-Diamino-1,3,5-triazines, process for their preparation, and their use as herbicides and plant growth regulators
TW200519088A (en)	2005-06-16	Aryl or heteroaryl amide compounds
BR9607017A (pt)	1997-10-28	Composto e uso do mesmo
EP0860428A3 (de)	2000-07-19	Sulfonamidderivate
EP1288199A4 (de)	2005-10-12	Mnp-12 inhibitoren
BR0011521A (pt)	2002-03-26	Composto nucleósidos de purina de 4' -c-etinila
HUP9802865A2 (hu)	1999-03-29	N-(szubsztituált fenil-)-pirazol-származékok, előállításuk és alkalmazásuk, a vegyületeket hatóanyagként tartalmazó parazitaellenes készítmények
MXPA02004440A (es)	2004-09-10	Derivados de pirrol como inhibidores de la fosfodiesterasa vii.
MY108076A (en)	1996-08-30	Cationic compound and cleaning composition.
DE69801594D1 (de)	2001-10-11	Kosmetische zusammensetzung enthaltend eine indigotyp-verbindung
NO20054791L (no)	2005-12-20	Forbindelser for behandling av stoffskiftesykdommer
MY118004A (en)	2004-08-30	Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
AU8581391A (en)	1992-07-02	Heterocyclic compounds
EP1357124A4 (de)	2004-02-04	Heterocyclische verbindungen und mittel, die die hirnfunktion verbessern und als wirkstoff diese verbindungen enthalten
SG146681A1 (en)	2008-10-30	4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
MEP12108A (en)	2010-06-10	Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them
DK0600950T3 (da)	1997-04-21	Tetrazolamider som inhibitorer af ACAT
CA2459887A1 (en)	2003-03-20	Carba-sugar amine derivative and glycolipid metabolic disorder treating agent containing the same as active ingredient
DK1161424T3 (da)	2004-09-13	Hidtil ukendte diazolderivater som serotonerge midler
EP1027880A3 (de)	2002-08-14	Verwendung von quaternären Ammoniumverbindungen als Antitranspirantien
YU28902A (sh)	2004-11-25	Fenil- i piridil-tetrahidro-piridini koji imaju tnf-inhibitorsku aktivnost